C. Sperti et al., EFFECT OF CHOLECYSTOKININ ANALOG CERULEIN AND CHOLECYSTOKININ ANTAGONIST LORGLUMIDE ON PANCREATIC CARCINOGENESIS IN THE RAT, Journal of surgical oncology, 57(1), 1994, pp. 11-16
The effects of the cholecystokinin (CCK)-analogue, caerulein, and CCK-
receptor antagonist lorglumide (CR-1409) on pancreatic carcinogenesis
induced by 7,12-dimethylbenz(a)anthracene (DMBA) were studied. One hun
dred thirty rats were divided into the following 10 treatment groups:
group 1, DMBA (2-3 mg); group 2, DMBA + caerulein (5 mug/kg); group 3,
DMBA + caerulein + CR-1409 (12 mg/kg); group 4, caerulein + DMBA; gro
up 5, caerulein + CR-1409 + DMBA; group 6, DMBA + CR-1409; group 7, CR
-1409 + DMBA; group 8, caerulein; group 9, CR-1409; and group 10, sham
operation + saline. DMBA was surgically implanted into the pancreas.
Caerulein and/or CR- 1409 was administered twice daily for 15 days aft
er (in groups 2, 3, and 6) or before (in groups 4, 5, and 7) DMBA impl
antation. Six months after carcinogen administration, all rats were sa
crificed and autopsied. The incidence of pancreatic cancer appeared si
gnificantly (P < 0.001) increased when caerulein was administered foll
owing DMBA implantation. CR-1409 significantly inhibited (P < 0.02) ca
erulein effects and reduced tumor growth when injected after carcinoge
n exposure. (C) 1994 Wiley-Liss, Inc.